Clindamycin/adapalene/benzoyl peroxide

Last updated

Clindamycin/adapalene/benzoyl peroxide
Combination of
Clindamycin Lincosamide antibacterial
Adapalene Retinoid
Benzoyl peroxide Oxidizing agent
Clinical data
Trade names Cabtreo
AHFS/Drugs.com Cabtreo
License data
Routes of
administration 		Topical
ATC code
Legal status
Legal status
Identifiers
KEGG

Clindamycin/adapalene/benzoyl peroxide, sold under the brand name Cabtreo, is a fixed-dose combination medication used for the treatment of acne. [2] It contains clindamycin 1.2%, as the phosphate, a lincosamide antibacterial; adapalene 0.15%, a synthetic retinoid; and benzoyl peroxide 3.1%, an oxidizing agent. [2] It is applied to the skin. [2]

Clindamycin/adapalene/benzoyl peroxide was approved for medical use in the United States in October 2023. [2] [3] It is the first triple-combination topical acne treatment approved by the US Food and Drug Administration. [3]

References

  1. ↑ "Regulatory Decision Summary for Cabtreo". Drug and Health Products Portal. 14 August 2024. Retrieved 27 December 2024.
  2. 1 2 3 4 5 "Cabtreo- clindamycin phosphate/benzoyl peroxide/adapalene gel". DailyMed. 27 October 2023. Archived from the original on 15 November 2023. Retrieved 15 November 2023.
  3. 1 2 "FDA Approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel For The Treatment Of Acne Vulgaris In Patients Twelve Years Of Age And Older". Bausch Health Companies Inc. (Press release). 20 October 2023. Archived from the original on 15 November 2023. Retrieved 15 November 2023.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.